{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiaijq64vgaxrpzoyiiewktnbo5nqocjpw5y4q22ohokssroidhb3y",
    "uri": "at://did:plc:wwyqal4cnqhuwyacdj7rqq3n/app.bsky.feed.post/3mg5oi6ml3ji2"
  },
  "path": "/t/generalizability-vs-transportability-in-trials/28551?page=3#post_60",
  "publishedAt": "2026-03-02T14:31:01.000Z",
  "site": "https://discourse.datamethods.org",
  "textContent": "Okay I will try to be very clear. There is on average a risk in each arm and on average a RD in each trial. This RD will vary from trial to trial based on each trials baseline risk (on average) because the RD is variation dependent. To avoid that a trial must deliver a variation independent effect (OR) from which we derive the clinically relevant RD based on our estimated patient related baseline risk. We are not talking about risk reduction here (which is a different ball game) but rather risk difference (RD). So I see no issues with absolute measures such as RD so long as they are computed properly. No one would report a RD alone in an RCT - it will always be paired with a relative effect measure and the RD, if reported, is applicable to patients like those in the trial only.",
  "title": "Generalizability vs. Transportability in Trials"
}